A few observations are in order. One should assume that Balzer didn't just show up on Medizone's doorstep June 7 so he could be introduced to the small gang of people who follow this company. He probably had been kicking the tires for a month or two and obviously thought that he could unlock some value here. Right now we do not know if any product has rolled off the line at SMTC. The last delay pushed product rollout to the end of May. We're in mid July. We should hope that testing protocols are now developed. I have no information regarding patents other that what I have read on this board. The stock has experienced some high percentage drops in the last few weeks culminating in a 30% cumulative decline during Balzer's time on the job. I don't take that stat as a negative because I believe the stock would be back in single digits (cents per share) if Balzer was not on the job. The business plan I hope for is that Balzer establishes the product, stamps the patent, and sells Medizone to a company that really can market Asepticsure full time to a wide variety of industries. Has anyone gotten wind of any patent delays?